Hepatitis C, Chronic Concept

subject area of

• A Patient with a Leg Rash, Pedal Edema, Renal Failure, and Thrombocytopenia  Academic Article
• A randomized study of alpha-interferon plus ribavirin for 6 months or 12 months for the treatment of chronic hepatitis C in patients with bleeding disorders  Academic Article
• Antiretroviral treatment change among HIV, hepatitis B virus and hepatitis C virus co-infected patients in the Australian HIV Observational Database  Academic Article
• Antiviral treatment for chronic hepatitis C in patients with human immunodeficiency virus  Academic Article
• Bone mineral density in haemophilia patients  Academic Article
• Chronic hepatitis C treatment outcomes in low- and middle-income countries: a systematic review and meta-analysis  Academic Article
• Clinical trial: exposure to ribavirin predicts EVR and SVR in patients with HCV genotype 1 infection treated with peginterferon alfa-2a plus ribavirin  Academic Article
• Cocaine/crack use is not associated with fibrosis progression measured by AST-to-Platelet Ratio Index in HIV-HCV co-infected patients: a cohort study  Academic Article
• Cost-effectiveness of daclatasvir plus sofosbuvir-based regimen for treatment of hepatitis C virus genotype 3 infection in Canada  Academic Article
• Direct-acting antiviral therapies for hepatitis C genotype 1 infection: a multiple treatment comparison meta-analysis  Academic Article
• Efficacy and Safety of Pegylated Interferon Alfa-2a or Alfa-2b Plus Ribavirin for the Treatment of Chronic Hepatitis C in Children and Adolescents: A Systematic Review and Meta-analysis  Academic Article
• Efficacy and safety of a two‐drug direct‐acting antiviral agent regimen ruzasvir 180 mg and uprifosbuvir 450 mg for 12 weeks in adults with chronic hepatitis C virus genotype 1, 2, 3, 4, 5 or 6  Academic Article
• Efficacy of 8 Weeks of Sofosbuvir, Velpatasvir, and Voxilaprevir in Patients With Chronic HCV Infection: 2 Phase 3 Randomized Trials  Academic Article
• Eliminating Structural Barriers: The Impact of Unrestricted Access on Hepatitis C Treatment Uptake Among People Living With Human Immunodeficiency Virus  Academic Article
• Estimating chronic hepatitis C prognosis using transient elastography‐based liver stiffness: A systematic review and meta‐analysis  Academic Article
• Estimation of fibrosis progression rates for chronic hepatitis C: a systematic review and meta-analysis update  Academic Article
• Expanding Access to Treatment for Hepatitis C in Resource-Limited Settings: Lessons From HIV/AIDS  Academic Article
• Global real‐world evidence of sofosbuvir/velpatasvir as simple, effective HCV treatment: Analysis of 5552 patients from 12 cohorts  Academic Article
• Glucocorticoid Receptors, Brain-Derived Neurotrophic Factor, Serotonin and Dopamine Neurotransmission are Associated with Interferon-Induced Depression  Academic Article
• HIV/HBV and HIV/HCV coinfection, and outcomes following highly active antiretroviral therapy  Academic Article
• Health care costs associated with hepatitis C virus infection in First Nations populations in Ontario: a retrospective matched cohort study  Academic Article
• Health state utilities associated with attributes of treatments for hepatitis C  Academic Article
• Hepatitis C Virus Testing of Persons Born During 1945–1965: Recommendations From the Centers for Disease Control and Prevention  Academic Article
• Hepatitis C virus infection characteristics and treatment outcomes in Canadian immigrants  Academic Article
• How much management is necessary? Sustaining the benefit of achieving a sustained virologic response to hepatitis C  Academic Article
• IL28B polymorphism (rs12979860) associated with clearance of HCV infection in Poland: Systematic review of its prevalence in chronic hepatitis C patients and general population frequency  Academic Article
• Impact of Asian Race on Response to Combination Therapy With Peginterferon Alfa-2a and Ribavirin in Chronic Hepatitis C  Academic Article
• Increased Eligibility for Treatment of Chronic Hepatitis C Infection with Shortened Duration of Therapy: Implications for Access to Care and Elimination Strategies in Canada  Academic Article
• Interventions to increase testing, linkage to care and treatment of hepatitis C virus (HCV) infection among people in prisons: A systematic review  Academic Article
• Ledipasvir-Sofosbuvir Plus Ribavirin in Treatment-Naive Patients With Hepatitis C Virus Genotype 3 Infection: An Open-Label Study  Academic Article
• Letter to the Editor  Academic Article
• Long Term Follow-Up of Patients with Chronic Hepatitis C Treated with Alpha Interferon  Academic Article
• Marijuana Use in Hepatitis C Infection does not Affect Liver Biopsy Histology or Treatment Outcomes  Academic Article
• Missed Opportunities for Hepatocellular Carcinoma Screening in an HIV/Hepatitis C Virus-Coinfected Cohort  Academic Article
• Network meta-analysis of direct-acting antivirals in combination with peginterferon–ribavirin for previously untreated patients with hepatitis C genotype 1 infection  Academic Article
• Oral prostaglandin (PGE2) therapy for chronic viral hepatitis B and C  Academic Article
• Outcomes of Chronic Hepatitis C Therapy in Patients Treated in Community Versus Academic Centres in Canada: Final Results of APPROACH (A Prospective Study of Peginterferon alfa-2a and Ribavirin at Academic and Community Centres in Canada)  Academic Article
• Paranoid psychosis and cognitive impairment associated with hepatitis C antiviral therapy  Academic Article
• Peginterferon Plus Ribavirin for Chronic Hepatitis C in Patients With Human Immunodeficiency Virus  Academic Article
• Peginterferon alpha-2a is associated with higher sustained virological response than peginterferon alfa-2b in chronic hepatitis C: Systematic review of randomized trials  Academic Article
• Peginterferon alpha-2a versus peginterferon alpha-2b for chronic hepatitis C  Academic Article
• Peginterferon plus ribavirin versus interferon plus ribavirin for chronic hepatitis C  Academic Article
• Prevalence of Hepatitis C Virus Infection in a Surgical Population of Southeast China: A Large-Scale Multicenter Study  Academic Article
• Prevalence of insulin resistance in chronic hepatitis C genotype 1 and 3 patients  Academic Article
• Progression of Liver Fibrosis and Modern Combination Antiretroviral Therapy Regimens in HIV-Hepatitis C–Coinfected Persons  Academic Article
• Real-world effectiveness of peginterferon α-2b plus ribavirin in a Canadian cohort of treatment-naïve chronic hepatitis C patients with genotypes 2 or 3: results of the PoWer and RediPEN studies  Academic Article
• Real-world impact of direct acting antiviral therapy on health-related quality of life in HIV/Hepatitis C co-infected individuals  Academic Article
• Recommendations for the identification of chronic hepatitis C virus (HCV) infection among persons born during 1945 through 1965  Academic Article
• Reply to: “Real-world experience of serial serum levels of GS-331007 in chronic hepatitis C hemodialysis patients during and after sofosbuvir/velpatasvir therapy”  Academic Article
• Retreatment with Pegylated Interferon Alpha-2a and Ribavirin in Patients with Chronic Hepatitis C Who Have Relapsed or Not Responded to a First Course of Pegylated Interferon-Based Therapy  Academic Article
• Salvage Therapy with Sofosbuvir/Velpatasvir/Voxilaprevir in DAA-experienced Patients: Results from a Prospective Canadian Registry  Academic Article
• Sofosbuvir/velpatasvir for 12 weeks in hepatitis C virus-infected patients with end-stage renal disease undergoing dialysis  Academic Article
• Suicide risk in hepatitis C and during interferon-alpha therapy: a review and clinical update  Academic Article
• The health impact of delaying direct‐acting antiviral treatment for chronic hepatitis C: A decision‐analytic approach  Academic Article
• The novel immunoregulatory molecule FGL2: A potential biomarker for severity of chronic hepatitis C virus infection  Academic Article
• Treatment responses in Asians and Caucasians with chronic hepatitis C infection  Academic Article